CCL28 and viral infectious disease: Our lab has previously demonstrated that GPI-anchored CCL28 (GPI-CCL28) acted as an effective adjuvant in an influenza VLP vaccine, which induced robust immune responses at systemic and mucosal compartments and provided significant cross-protection against heterologous viral infection [84] (Figure 1B).